134 related articles for article (PubMed ID: 37586854)
1. Differentiation of Discordant Lesions on Dual-Tracer PET/CT (
Chalikandy A; Yadav S; Basu S
J Nucl Med Technol; 2023 Dec; 51(4):339-342. PubMed ID: 37586854
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. The Triple-Tracer strategy against Metastatic PrOstate cancer (3TMPO) study protocol.
Pouliot F; Beauregard JM; Saad F; Trudel D; Richard PO; Turcotte É; Rousseau É; Probst S; Kassouf W; Anidjar M; Camirand Lemyre F; Bouvet GF; Neveu B; Tétu A; Guérin B
BJU Int; 2022 Sep; 130(3):314-322. PubMed ID: 34674367
[TBL] [Abstract][Full Text] [Related]
4.
Parghane RV; Basu S
J Nucl Med Technol; 2023 Sep; 51(3):261-262. PubMed ID: 36041875
[TBL] [Abstract][Full Text] [Related]
5. Small Cell Transformation of Metastatic Prostate Adenocarcinoma Diagnosed by Dual-Tracer PET/CT (
Parghane R; Basu S
J Nucl Med Technol; 2019 Mar; 47(1):85-87. PubMed ID: 30139889
[TBL] [Abstract][Full Text] [Related]
6. Role of FDG PET/CT in Management of Patients with Prostate Cancer.
Sutherland DEK; Azad AA; Murphy DG; Eapen RS; Kostos L; Hofman MS
Semin Nucl Med; 2024 Jan; 54(1):4-13. PubMed ID: 37400321
[TBL] [Abstract][Full Text] [Related]
7. Differentiating benign and malignant pancreatic masses: Ga-68 PSMA PET/CT as a new diagnostic avenue.
Krishnaraju VS; Kumar R; Mittal BR; Sharma V; Singh H; Nada R; Bal A; Rohilla M; Singh H; Rana SS
Eur Radiol; 2021 Apr; 31(4):2199-2208. PubMed ID: 33001304
[TBL] [Abstract][Full Text] [Related]
8.
Qi Z; Yao X; Su M; Huang R
Hell J Nucl Med; 2023; 26(2):155-156. PubMed ID: 37527052
[TBL] [Abstract][Full Text] [Related]
9. Exploratory analysis of 64 CuCl 2 PET-CT imaging in carcinoma prostate and its comparison with 68 Ga-PSMA-11 and 18 F-FDG PET-CT.
Nazar AK; Kalshetty A; Chakravarty R; Chakraborty S; Basu S
Nucl Med Commun; 2023 Oct; 44(10):910-923. PubMed ID: 37578310
[TBL] [Abstract][Full Text] [Related]
10. 68 Ga-FAPI PET/CT Detected Non-PSMA/FDG-Avid Primary Tumor in De Novo Metastatic Prostate Cancer.
Pang Y; Meng T; Xu W; Shang Q; Chen H
Clin Nucl Med; 2022 Dec; 47(12):1108-1111. PubMed ID: 35961368
[TBL] [Abstract][Full Text] [Related]
11. Visualization of Intermetastatic Heterogeneity in Mixed Neuroendocrine Carcinoma-Acinar Adenocarcinoma of the Prostate by 68 Ga-PSMA, 68 Ga-FAPI, and 18 F-FDG PET/CT.
Cai J; Xu W; Meng T; Pang Y; Chen H
Clin Nucl Med; 2023 Aug; 48(8):743-745. PubMed ID: 37220226
[TBL] [Abstract][Full Text] [Related]
12. 68 Ga-PSMA-11 and 18 F-FDG PET/CT in a Case of Ductal Adenocarcinoma of the Prostate.
Qiu S; Dong A; Zhu Y; Zuo C
Clin Nucl Med; 2022 Sep; 47(9):836-838. PubMed ID: 35439204
[TBL] [Abstract][Full Text] [Related]
13. Adenocarcinoma Prostate With Neuroendocrine Differentiation: Potential Utility of 18F-FDG PET/CT and 68Ga-DOTANOC PET/CT Over 68Ga-PSMA PET/CT.
Parida GK; Tripathy S; Datta Gupta S; Singhal A; Kumar R; Bal C; Shamim SA
Clin Nucl Med; 2018 Apr; 43(4):248-249. PubMed ID: 29474196
[TBL] [Abstract][Full Text] [Related]
14. Different Appearances of 3 Malignancies in 68Ga-PSMA-11 Versus 18F-FDG PET/CT.
Weitzer F; Nazerani-Hooshmand T; Aigner RM; Pernthaler B
Clin Nucl Med; 2021 Jul; 46(7):e358-e359. PubMed ID: 34081054
[TBL] [Abstract][Full Text] [Related]
15. Concomitant Prostate Cancer and Hodgkin Lymphoma: A Differential Diagnosis Guided by a Combined 68Ga-PSMA-11 and 18F-FDG PET/CT Approach.
Miceli A; Riondato M; D'Amico F; Donegani MI; Piol N; Mora M; Spina B; Morbelli S; Bauckneht M
Medicina (Kaunas); 2021 Sep; 57(9):. PubMed ID: 34577898
[TBL] [Abstract][Full Text] [Related]
16. Primary Hepatocellular Carcinoma With Intense 68Ga-PSMA Uptake But Slight 18F-FDG Uptake on PET/CT Imaging.
Erhamamci S; Aslan N
Clin Nucl Med; 2020 Mar; 45(3):e176-e177. PubMed ID: 31977478
[TBL] [Abstract][Full Text] [Related]
17. A Comparison of 18 F-FDG PET/CT and 68 Ga-PSMA PET/CT in Detecting Osteonecrosis of the Jaw in a Patient With Prostate Cancer.
Öztürk AE; Şahin R; Ergül N; Çermik TF; Arslan E
Clin Nucl Med; 2024 Feb; 49(2):e68-e69. PubMed ID: 38170920
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic Radiotherapy for Lesions Detected via
Pan J; Wei Y; Zhang T; Liu C; Hu X; Zhao J; Gan H; Liu W; Zhu B; Wu J; Wang B; Song S; Ye D; Zhu Y
Eur Urol Oncol; 2022 Aug; 5(4):420-427. PubMed ID: 35304107
[TBL] [Abstract][Full Text] [Related]
19. PET radiotracers for whole-body in vivo molecular imaging of prostatic neuroendocrine malignancies.
Cohen D; Hazut Krauthammer S; Fahoum I; Kesler M; Even-Sapir E
Eur Radiol; 2023 Sep; 33(9):6502-6512. PubMed ID: 37052659
[TBL] [Abstract][Full Text] [Related]
20. 18F-FDG, 68Ga-DOTATATE and 68Ga-PSMA Positive Metastatic Large Cell Neuroendocrine Prostate Tumor.
Acar E; Kaya GÇ
Clin Nucl Med; 2019 Jan; 44(1):53-54. PubMed ID: 30325820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
